Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

Papp, Kim; Gordon, Ken; Langley, Richard; Lebwohl, Mark; Gottlieb, Alice B.; Rastogi, Shipra; Pillai, Radhakrishnan; Israel, Robert J.

doi:10.1111/bjd.16464

Cited by 51 publications

(70 citation statements)

References 19 publications

(47 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, rescue with brodalumab was effective regardless of the prior use of a biologic. This observation is in accordance with a study by Papp et al . The safety profile associated with switching to brodalumab appears favourable and similar to those previously reported …”

supporting

confidence: 93%

Is an anti‐interleukin‐17 receptor able to do the job when an anti‐interleukin‐12/23 has failed?

Montaudié

2019

Br J Dermatol

View full text Add to dashboard Cite

show abstract

supporting

confidence: 93%

Is an anti‐interleukin‐17 receptor able to do the job when an anti‐interleukin‐12/23 has failed?

Montaudié

2019

Br J Dermatol

View full text Add to dashboard Cite

show abstract

“…PASI 75 responses of the reference arm in included studies were utilized to inform baseline event rates. Prior exposure to biological therapies varies across trials in psoriasis and is thought to be a potential effect modifier (20,21); therefore, a sensitivity analysis was carried out excluding studies which included <5% of patients with prior experience of biologics or which did not report this information.…”

Section: Discussionmentioning

confidence: 99%

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

Yasmeen¹,

Sawyer²,

Malottki³

et al. 2020

Journal of Dermatological Treatment

102

View full text Add to dashboard Cite

Purpose: To compare PASI outcomes of approved biologics and apremilast after 1 year of treatment. Methods: A systematic review identified RCTs and long-term extensions reporting PASI 75, 90, and 100 responses in adults with moderate-to-severe psoriasis. Data for analysis were modeled using a Bayesian multinomial likelihood model with probit link. Results: Twenty-eight studies reporting PASI responses were included in the network meta-analysis. Differences in study design led to a stepwise approach to synthesis, consisting of two analyses. The primary analysis included nine RCTs investigating comparative efficacy at 1 year. Results indicated risankizumab, brodalumab, and guselkumab were the most effective therapies, followed by ixekizumab and secukinumab; all demonstrated superiority to ustekinumab and etanercept. The secondary analysis extended the primary analysis with 19 further studies comparing active interventions to placebo outcomes extrapolated from induction. The interventions generating the highest PASI response were the same as the primary analysis. These therapies were more effective than apremilast, ustekinumab, adalimumab, certolizumab, etanercept, and infliximab. Conclusions: This NMA demonstrated that evaluated IL-17 and IL-23 inhibitors outperformed other biological therapies after 1 year. Risankizumab had a higher probability of achieving PASI outcomes than all other biologics, except brodalumab and guselkumab, where no significant difference could be concluded.

show abstract

“…The difference in PASI 100 response rates between Asian and non‐Asian patients may be due to random variability and the small proportions of patients who achieved a PASI 100 response. The results of previous studies with brodalumab and ustekinumab suggest that the higher proportion of patients with prior use of systemic and biologic agents in the Asian population may also play a role.…”

Section: Discussionmentioning

confidence: 99%

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

Reich

Song

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Guselkumab, an interleukin‐23 blocker, was superior to placebo and adalimumab and well‐tolerated in phase 3 psoriasis studies (VOYAGE 1 and VOYAGE 2). This analysis evaluated the consistency of response in the Asian subpopulation in VOYAGE 1 and VOYAGE 2. Study designs were identical through week 24; patients were randomized to guselkumab, placebo, or adalimumab. Investigator's Global Assessment (IGA), Psoriasis Area and Severity Index (PASI), safety, and pharmacokinetic and immunogenicity data from VOYAGE 1 and VOYAGE 2 were pooled and compared by race (Asian, n = 199; non‐Asian, n = 1630). At week 16, treatment differences between guselkumab and placebo were 78.2 (95% confidence interval [CI], 66.9–89.6) and 76.4 (95% CI, 72.7–80.2) percentage points for IGA 0/1 (score of 0 or 1) and 70.1 (95% CI, 60.0–80.1) and 68.5 (95% CI, 64.9–72.2) percentage points for PASI 90 (≥90% improvement) in the Asian and non‐Asian populations, respectively. Treatment differences between guselkumab and adalimumab were 31.1 (95% CI, 17.7–44.6) and 16.1 (95% CI, 11.2–21.0) percentage points for IGA 0/1 and 24.9 (95% CI, 9.4–40.5) and 23.2 (95% CI, 17.7–28.6) percentage points for PASI 90 in the Asian and non‐Asian populations, respectively. Similar results were observed at week 24. Safety was generally similar between populations and among treatment groups. Median serum guselkumab concentrations over time were comparable between the populations. Comparable responses between the Asian and non‐Asian populations in this analysis suggest that the overall efficacy, safety, and the resulting benefit/risk analyses from VOYAGE 1 and VOYAGE 2 are applicable to Asian populations.

show abstract

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3

Cited by 51 publications

References 19 publications

Is an anti‐interleukin‐17 receptor able to do the job when an anti‐interleukin‐12/23 has failed?

Is an anti‐interleukin‐17 receptor able to do the job when an anti‐interleukin‐12/23 has failed?

Targeted therapies for patients with moderate-to-severe psoriasis: a systematic review and network meta-analysis of PASI response at 1 year

Consistent responses with guselkumab treatment in Asian and non‐Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2

Contact Info

Product

Resources

About